Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
874.00
+5.73 (0.66%)
At close: Apr 28, 2026, 4:00 PM EDT
870.91
-3.09 (-0.35%)
Pre-market: Apr 29, 2026, 8:18 AM EDT
Eli Lilly Revenue
In the year 2025, Eli Lilly had annual revenue of $65.18B with 44.70% growth. Eli Lilly had revenue of $19.29B in the quarter ending December 31, 2025, with 42.55% growth.
Revenue (ttm)
$65.18B
Revenue Growth
+44.70%
P/S Ratio
12.00
Revenue / Employee
$1,303,580
Employees
50,000
Market Cap
782.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.18B | 20.14B | 44.70% |
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
LLY News
- 2 hours ago - Eli Lilly investors are eager for Foundayo insight after early launch data - Reuters
- 1 day ago - Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion - Reuters
- 1 day ago - Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial - Reuters
- 1 day ago - Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs - CNBC
- 1 day ago - As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst - Barrons
- 2 days ago - Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion - WSJ
- 2 days ago - Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion - Reuters
- 2 days ago - Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera - PRNewsWire